PSI Stories

At PSI, researchers decipher the structure of the proteins in bacteria and viruses. This knowledge can aid, for example, in the development of drugs against infectious diseases. But before the investigation can begin, an extremely tricky problem has to be solved: the crystallisation of the molecules.

Researchers have coaxed a secret out of the vital protein cytochrome c that it kept well-hidden up to now. Measurements at the X-ray free-electron laser SwissFEL reveal structural changes that science had previously ruled out for this kind of biomolecule.

PSI congratulates Emmanuelle Charpentier and Jennifer Doudna on winning this year's Nobel Prize in Chemistry. Experiments at the Swiss Light Source SLS in 2013 made it possible to elucidate the structure of the protein complex CRISPR-Cas9.

PSI researchers have found a more effective treatment for a form of thyroid cancer – and with fewer side effects – by increasing the uptake of the cancer drug in tumour cells. The results have been published in the medical journal Theranostics.

An international team of scientists has identified a novel driver of new aerosol particle formation in the Arctic: iodic acid, a chemical compound, which had not previously been observed in the region.

An international expedition with the participation of the Paul Scherrer Institute PSI discovers advanced glacial melting at an elevation of more than 4,000 metres on the Grand Combin in Valais. In the Alps, it may almost be too late for the Ice Memory project, which aims to save ice cores as a climate archive for future generations of researchers.

The world of microbes and viruses is extremely old and exceedingly diverse. With the large research facilities at PSI, researchers are peering deep inside this alien cosmos and investigating, above all, the proteins of these exotic beings.

Future batteries need to store more energy, have longer life, and be safer and more environmentally friendly than today's batteries. The European initiative BATTERY 2030+, in which PSI is participating, is intended to help achieve these goals.

At PSI, researchers are screening molecule fragments to see if these bind to important proteins of the coronavirus SARS-CoV-2 and thus have the potential to disable it. They are hoping the many individual pieces of information will yield an answer as to what an effective drug might look like.

The Swiss Light Source SLS is set to get an upgrade to make excellent research possible in the coming decades as well. Hans Braun, SLS 2.0 project leader, talks about this undertaking in an interview.